- Home
- EVT vs ARQT Comparison
EVT vs ARQT Comparison
Compare EVT & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVT
- ARQT
- Stock Information
- Founded
- EVT 2003
- ARQT 2016
- Country
- EVT United States
- ARQT United States
- Employees
- EVT N/A
- ARQT N/A
- Industry
- EVT Finance Companies
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- EVT Finance
- ARQT Health Care
- Exchange
- EVT Nasdaq
- ARQT Nasdaq
- Market Cap
- EVT 1.9B
- ARQT 2.1B
- IPO Year
- EVT N/A
- ARQT 2020
- Fundamental
- Price
- EVT $24.54
- ARQT $20.74
- Analyst Decision
- EVT
- ARQT Strong Buy
- Analyst Count
- EVT 0
- ARQT 7
- Target Price
- EVT N/A
- ARQT $19.00
- AVG Volume (30 Days)
- EVT 115.5K
- ARQT 1.9M
- Earning Date
- EVT 01-01-0001
- ARQT 10-28-2025
- Dividend Yield
- EVT 8.32%
- ARQT N/A
- EPS Growth
- EVT N/A
- ARQT N/A
- EPS
- EVT 6.63
- ARQT N/A
- Revenue
- EVT $69,404,302.00
- ARQT $263,464,999.00
- Revenue This Year
- EVT N/A
- ARQT $72.46
- Revenue Next Year
- EVT N/A
- ARQT $31.69
- P/E Ratio
- EVT $3.55
- ARQT N/A
- Revenue Growth
- EVT N/A
- ARQT 99.50
- 52 Week Low
- EVT $19.20
- ARQT $8.03
- 52 Week High
- EVT $25.83
- ARQT $21.30
- Technical
- Relative Strength Index (RSI)
- EVT 60.30
- ARQT 68.31
- Support Level
- EVT $24.41
- ARQT $16.68
- Resistance Level
- EVT $24.52
- ARQT $21.30
- Average True Range (ATR)
- EVT 0.26
- ARQT 1.00
- MACD
- EVT 0.03
- ARQT 0.25
- Stochastic Oscillator
- EVT 72.65
- ARQT 89.84
About EVT Eaton Vance Tax Advantaged Dividend Income Fund of Beneficial Interest
EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND is a diversified, closed-end management investment company. Its objective is to provide a high level of after-tax total return consisting mainly of tax-advantaged dividend income and capital appreciation. The fund pursues its objective by investing in dividend-paying common and preferred stocks. Its portfolio of investments consists of electric utilities, energy equipment and services, food products, health care providers and services, internet software and services, and other areas.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.